Cytonics
Blood & Organ Banks · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
658 W Indiantown Rd Ste 214, Jupiter, Fl...Phone Number
(561) 406-2864Website
www.cytonics.comRevenue
<$5 MillionIndustry
ZI Rank: 3
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
2
1
2
3
About Cytonics
Cytonics Corporation is a clinical-stage biotechnology company focused on developing innovative treatments for osteoarthritis, the most common joint disease. Utilizing Alpha-2-Macroglobulin (A2M), Cytonics has created a novel biologic, CYT-108, which aims to target the molecular causes of cartilage degradation and potentially reverse osteoarthritis progression. The company seeks to provide effective therapies where traditional medications have failed, emphasizing a patient-centered approach. Cytonics is committed to pioneering drug discovery and addressing the shortcomings of existing pharmaceutical solutions.Explore more
Cytonics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cytonics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Cytonics had a recent Job posting/layoffs
Check if Cytonics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Cytonics launches new products
Check out if Cytonics is spiking on competitors!
Funding: Get notified immidiatlly once Cytonics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Cytonics
Earning: See what the market has to say on Cytonics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Cytonics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Cytonics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Cytonics
Compare insights from companies similar to Cytonics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cytonics is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Cytonics is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Cytonics.
Cytonics Tech Stack
A closer look at the technologies used by Cytonics
See more technologies
Cytonics News & Media
Cytonics Announces Successful Completion of Phase 1 Study for First Nine Patients in CYT-108 Clinical Trial
– No adverse events reported; CYT-108 progressing as a potential disease-modifying therapy for osteoarthritis – JUPITER, Fla., Jan. 21, 2025 /PRNewswire/ -- Cytonics Corporation, a private biotechnology company developing cutting-edge biologic therapies for musculoskeletal conditions,...Cytonics Announces Completion Of Enrollment For Phase 1 Clinical Study Evaluating CYT-108, A Novel Recombinant Protease Inhibitor, In Patients Suffering From Osteoarthritis Of The Knee
Top-line results from Phase 1 study expected in second quarter of 2025 JUPITER, Fla., Sept. 6, 2024 /PRNewswire/ -- Cytonics Corporation, a private biotechnology company developing biologic therapies for inflammatory musculoskeletal conditions, today announced completion of enrollment for...Cytonics Announces Initiation Of First-In-Human Phase 1 Clinical Study For CYT-108 In Patients Suffering From Osteoarthritis Of The Knee
JUPITER, Fla., July 15, 2024 /PRNewswire/ -- Cytonics Corporation, a private biotechnology company developing biologic therapies for musculoskeletal ailments, today announced initiation of enrollment for its Phase 1 clinical study of CYT-108, a recombinant variant of the...Cytonics Corporation to Webcast Live at VirtualInvestorConferences.com on September 15th at 12pm EST
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cytonics
Sign Up For FreeTo access detailed company insights
Cytonics Corporation is a clinical-stage biotechnology company focused on developing innovative treatments for osteoarthritis, the most common joint disease. Utilizing Alpha-2-Macroglobulin (A2M), Cytonics has created a novel biologic, CYT-108, which aims to target the molecular causes of cartilage degradation and potentially reverse osteoarthritis... Read More
